-
1دورية أكاديميةBrentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma.
المؤلفون: Sasse, Stephanie, Rothe, Achim, Goergen, Helen, Eichenauer, Dennis A., Lohri, Andreas, Kreher, Stephan, Jäger, Ulrich, Bangard, Christopher, Kuhnert, Georg, Böll, Boris, von Tresckow, Bastian, Engert, Andreas
المصدر: Leukemia & Lymphoma; Oct2013, Vol. 54 Issue 10, p2144-2148, 5p
مصطلحات موضوعية: HEALTH outcome assessment, CANCER relapse, DISEASE relapse, STEM cell transplantation, COMPLICATIONS from organ transplantation, HODGKIN'S disease treatment, SALVAGE therapy, PATIENTS
-
2دورية أكاديمية
المؤلفون: Rothe, Achim1,2, Sasse, Stephanie1,2, Goergen, Helen1,2, Eichenauer, Dennis A.1,2, Lohri, Andreas3, Jäger, Ulrich4, Bangard, Christopher5, Boll, Boris1,2, von Bergwelt Baildon, Michael1, Theurich, Sebastian1, Borchmann, Peter1,2, Engert, Andreas1,2 a.engert@uni-koeln.de
المصدر: Blood. 8/16/2012, Vol. 120 Issue 7, p1470-1472. 3p.
مصطلحات موضوعية: *HEMATOLOGIC malignancies, *ANTINEOPLASTIC agents, *CANCER relapse, *HODGKIN'S disease, *DRUG efficacy
مصطلحات جغرافية: UNITED States
الشركة/الكيان: UNITED States. Food & Drug Administration